Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
14990 | 669 | 37.2 | 89% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1181 | 8908 | ENDOTHELIN//ENDOTHELIN 1//ENDOTHELIN RECEPTORS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MOL PATHOL ULTRASTRUCT | Address | 42 | 78% | 4% | 28 |
2 | ENDOTHELIN AXIS | Author keyword | 26 | 80% | 2% | 16 |
3 | ZD4054 | Author keyword | 17 | 72% | 2% | 13 |
4 | ZIBOTENTAN | Author keyword | 15 | 63% | 2% | 15 |
5 | ATRASENTAN | Author keyword | 13 | 43% | 3% | 23 |
6 | CD10 | Author keyword | 8 | 13% | 8% | 53 |
7 | CANC INFECT DISCOVERY MED | Address | 6 | 100% | 1% | 4 |
8 | ENDOTHELIN A RECEPTOR | Author keyword | 5 | 20% | 3% | 21 |
9 | ETAR | Author keyword | 4 | 40% | 1% | 8 |
10 | CD10 EXPRESSION | Author keyword | 3 | 60% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ENDOTHELIN AXIS | 26 | 80% | 2% | 16 | Search ENDOTHELIN+AXIS | Search ENDOTHELIN+AXIS |
2 | ZD4054 | 17 | 72% | 2% | 13 | Search ZD4054 | Search ZD4054 |
3 | ZIBOTENTAN | 15 | 63% | 2% | 15 | Search ZIBOTENTAN | Search ZIBOTENTAN |
4 | ATRASENTAN | 13 | 43% | 3% | 23 | Search ATRASENTAN | Search ATRASENTAN |
5 | CD10 | 8 | 13% | 8% | 53 | Search CD10 | Search CD10 |
6 | ENDOTHELIN A RECEPTOR | 5 | 20% | 3% | 21 | Search ENDOTHELIN+A+RECEPTOR | Search ENDOTHELIN+A+RECEPTOR |
7 | ETAR | 4 | 40% | 1% | 8 | Search ETAR | Search ETAR |
8 | CD10 EXPRESSION | 3 | 60% | 0% | 3 | Search CD10+EXPRESSION | Search CD10+EXPRESSION |
9 | ENDOTHELIN B RECEPTOR | 2 | 13% | 2% | 14 | Search ENDOTHELIN+B+RECEPTOR | Search ENDOTHELIN+B+RECEPTOR |
10 | ENDOTHELIN RECEPTOR A | 2 | 26% | 1% | 5 | Search ENDOTHELIN+RECEPTOR+A | Search ENDOTHELIN+RECEPTOR+A |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ATRASENTAN | 13 | 47% | 3% | 21 |
2 | EMERGING ROLE | 6 | 13% | 6% | 41 |
3 | CD10 NEUTRAL ENDOPEPTIDASE 2411 | 5 | 55% | 1% | 6 |
4 | OSTEOBLASTIC BONE METASTASES | 4 | 33% | 1% | 9 |
5 | B RECEPTOR EXPRESSION | 3 | 32% | 1% | 9 |
6 | PROMOTE INVASIVE BEHAVIOR | 3 | 100% | 0% | 3 |
7 | RECEPTOR ANTAGONIST ZD4054 | 3 | 100% | 0% | 3 |
8 | LYMPHOBLASTIC LEUKEMIA ANTIGEN | 3 | 19% | 2% | 15 |
9 | CONVERTING ENZYME 1 EXPRESSION | 3 | 60% | 0% | 3 |
10 | EXTRACELLULAR CA2 INFLUX | 3 | 60% | 0% | 3 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Endothelin 1 in cancer: biological implications and therapeutic opportunities | 2013 | 25 | 141 | 71% |
The emerging role of endothelin-1 in the pathogenesis of subchondral bone disturbance and osteoarthritis | 2015 | 1 | 86 | 41% |
The endothelin axis: Emerging role in cancer | 2003 | 333 | 61 | 74% |
Role of the endothelin axis and its antagonists in the treatment of cancer | 2011 | 48 | 109 | 55% |
Endothelin receptor antagonism and cancer | 2009 | 21 | 27 | 89% |
A review of the profile of endothelin axis in cancer and its management | 2014 | 4 | 99 | 56% |
The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy | 2008 | 46 | 82 | 71% |
Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054 | 2009 | 33 | 21 | 52% |
Targeting the endothelin axis in prostate carcinoma | 2012 | 16 | 38 | 53% |
Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer | 2011 | 35 | 71 | 37% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MOL PATHOL ULTRASTRUCT | 42 | 78% | 4.2% | 28 |
2 | CANC INFECT DISCOVERY MED | 6 | 100% | 0.6% | 4 |
3 | MOL PATHOL A | 1 | 50% | 0.3% | 2 |
4 | EA 3515 | 1 | 40% | 0.3% | 2 |
5 | DIAGNOST NEW TECHNOL | 1 | 50% | 0.1% | 1 |
6 | DIPARTIMENTO RIC TRASLAZIONALE NUOVE TECNOL MED | 1 | 50% | 0.1% | 1 |
7 | DRUG DEVCANC THER Y | 1 | 50% | 0.1% | 1 |
8 | EXAMINE | 1 | 50% | 0.1% | 1 |
9 | GENITOUINARY MED ONCOL | 1 | 50% | 0.1% | 1 |
10 | LINUS PAULING SCI 479 | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000178265 | NEUROSYST//MOL NEUROBIOL PAIN//BMS182874 5 DIMETHYLAMINO N 3 4 DIMETHYL 5 ISOXAZOLYD 1 NAPHTHALENESULFONAMIDE |
2 | 0.0000144494 | ENDOTHELIN//ENDOTHELIN 1//BQ 123 |
3 | 0.0000141011 | ENDOTHELIN CONVERTING ENZYME//PHOSPHORAMIDON//BIG ENDOTHELIN |
4 | 0.0000139952 | THROMBOXANE A2 PROSTACYCLIN BALANCE//SIGNALISAT REGULAT CELLULAI//U361 |
5 | 0.0000105661 | ENDOTHELIN 3//ETB RECEPTOR//BARREL ROLLING |
6 | 0.0000104194 | NORBORMIDE//LOE 908//RAT TOXICANT |
7 | 0.0000103252 | LONGEV SCI//HOSP GERIATR MED//TORAT MED |
8 | 0.0000055267 | NEUTRAL ENDOPEPTIDASE//OMAPATRILAT//VASOPEPTIDASE INHIBITOR |
9 | 0.0000053227 | ABIRATERONE//ENZALUTAMIDE//CASTRATION RESISTANT PROSTATE CANCER |
10 | 0.0000046556 | OSTEOBLASTIC METASTASIS//3 D COLLAGEN//AHTO 7 |